ZMR

Non-Invasive Prenatal Testing (NIPT) Market on Track to Reach $1,086.36 million by 2022

Press Release   •   Jan 19, 2018 02:16 EST

Zion Market Research has published a new report titled “Non-Invasive Prenatal Testing (NIPT) Market by Test Type (Panel 1, Panel 2 and Panel 3) and End-users (Hospitals, Diagnostic Centers, and Maternity Clinics): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2016 - 2022”. According to the report, global non-invasive prenatal testing (NIPT) market was valued at approximately USD 590.32 million in 2016 and is expected to generate revenue of around USD 1,086.36 million by end of 2022, growing at a CAGR of around 10.7% between 2017 and 2022.

Request For Free Sample Report https://goo.gl/9Dk6Fi

Prenatal screening and diagnosis involve testing for conditions in a fetus before it is born, with the aim of detecting causes of birth defects, abnormalities, and genetic conditions. Advancing the prenatal care services provided across the globe has become an uphill battle for medical practitioners and drug makers. Fortunately, this struggle is being eased by the active participation of parents from all around the world in protecting the health of their soon-to-be-born babies through prenatal disease detection methods. Noninvasive prenatal testing (NIPT) procedures are, hence, being rapidly adopted, which is prompting healthcare service providers to increase their focus on such prenatal diagnosis & screening services. Application of the technique to analyze approximately 20,000 genetic features in a single reaction in a sensitive and accurate manner for detection of a wide range of genetic disorders with fewer false positives is expected to propel the demand for NIPT products in the coming years.

The vendors are increasingly entering into partnerships and collaborations to extend their product offerings, increase their market shares, and expand their operations. These partnerships and collaborations help vendors enhance their R&D capabilities for manufacturing innovative devices that meet consumer needs. For instance, in 2015, Human Longevity entered into collaboration with Roche Diagnostics to conduct whole-genome sequencing of Roche Diagnostics' subsidiary Genentech's de-identified samples. The partnership helped Roche Diagnostics analyze patient samples based on precise genetic categories and discover new diagnostics and targeted therapies. These partnerships and collaborative activities are accelerating drug discovery efforts, which will lead to the development of new therapies to detect chromosomal abnormalities in neonates. To increase the adoption of new non-invasive tests, many companies focus on developing and strengthening their research infrastructure to develop efficient NIPTs. The competitive environment in this market is expected to intensify with an increase in product/service extensions, technological innovations, and mergers and acquisitions.

Inquiry more about this report:  https://goo.gl/hUrRHq

Based on test type, the non-invasive prenatal testing market is been segmented into panel 1, panel 2 and panel 3 tests. Based on end-user the non-invasive prenatal testing market is segmented into hospitals, diagnostic centers, and maternity clinics.

The global NIPT market is highly fragmented owing to the presence of several well-established global and regional vendors. The majority of vendors are looking to expand their businesses in the APAC region, which is a major untapped market that is likely to grow at a rapid pace during the forecast period. To increase the adoption of new non-invasive tests, many companies focus on developing and strengthening their research infrastructure to develop efficient NIPTs. The competitive environment in this market is expected to intensify with an increase in product/service extensions, technological innovations, and mergers and acquisitions.

Browse the full report at: https://goo.gl/tJB8h4

Some of the key players in the non-invasive prenatal testing market include Ariosa Diagnostics, Inc., Berry Genomics Co., Ltd, BGI Diagnostics, Illumina, Inc., LifeCodexx AG, Natera, Inc., Sequenom Laboratories, and Quest Diagnostics, Inc. The participants are engaged in the development and licensing of the software and cloud-based distribution model to enhance technology transfer. For instance, Natera underwent a licensing agreement with Unilab, which enables Unilab to access the proprietary protocols and key technology of Natera, thus driving revenue share of the company in reproductive genetic testing.

Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.